Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
Prime Drink Group Announces Change of Auditor
08:30pm, Friday, 04'th Jul 2025
MONTREAL, July 04, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime”) announces that it has changed its auditors from MNP LLP ("Former Auditor") to Horizon Assurance LLP ("Succ
Prime Drink Group Announces Private Placement
07:11pm, Wednesday, 02'nd Jul 2025
MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it will proceed with a best efforts non-brokered private placement off
Prime Drink Group Announces Launch of Rights Offering
06:20pm, Wednesday, 18'th Jun 2025
MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is undertaking a rights offering (the “Rights Offering”). The C
Prime Drink Group Provides an Update on Its Bottling Subsidiary Receivership
08:21pm, Tuesday, 10'th Jun 2025
MONTREAL, June 10, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that its bottling subsidiary, formerly known as Triani Canada Inc. (“Tria
Prime Medicine to Participate in Upcoming Investor Conferences
08:00am, Thursday, 29'th May 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivit
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
10:25am, Thursday, 08'th May 2025
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
08:00am, Thursday, 08'th May 2025
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class progra
Prime Drink Group Provides an Update to Its Subsidiary Restructuring
12:53pm, Monday, 07'th Apr 2025
MONTREAL, April 07, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to the termination of the forbearance agreements Roynat Inc.
Why Prime Medicine Stock Was Climbing Higher This Week
06:48pm, Thursday, 20'th Mar 2025
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Mark
Why Prime Medicine Stock Is Soaring Today
02:56pm, Wednesday, 19'th Mar 2025
Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
07:00am, Tuesday, 18'th Mar 2025
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP --
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
08:00am, Friday, 28'th Feb 2025
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
08:00am, Monday, 24'th Feb 2025
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap
